

1 **Acute pharmacodynamic responses to exenatide:**

2 **Drug-induced increases in insulin secretion and glucose effectiveness**

3
4 Simeon I. Taylor MD, PhD¹ | May E. Montasser PhD¹ | Ashley H. Yuen MD¹ |

5 Hubert Fan² | Zhinoosossadat Shahidzadeh Yazdi MD¹ | Hilary B. Whitlatch MD¹ |

6 Braxton D. Mitchell PhD, MPH¹ | Alan R. Shuldiner MD¹ | Ranganath Muniyappa MD PhD² |

7 Elizabeth A. Streeten MD¹ | Amber L. Beitelshees PharmD, MPH¹

8
9 ¹ Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of
10 Maryland School of Medicine, Baltimore, MD 21201, USA

11 ² Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and
12 Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

13
14 **Correspondence**

15 Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine,
16 Baltimore, MD 21201, USA

17 Email: staylor2@som.umaryland.edu

18 **Funding information:** American Diabetes Association (1-16-ICTS-112) and National Institute of
19 Diabetes and Digestive and Kidney Disease (R01DK130238, T32DK098107, and
20 P30DK072488)

21 **Trial registration:** NCT05762744 (clinicaltrials.gov)

22 **Study review and approval:** Institutional Review Board of the University of Maryland Baltimore

24 **ABSTRACT**

25 **Background:** GLP1R agonists provide multiple benefits to patients with type 2 diabetes –
26 including improved glycemic control, weight loss, and decreased risk of major adverse
27 cardiovascular events. Because drug responses vary among individuals, we initiated
28 investigations to identify genetic variants associated with the magnitude of drug responses.

29 **Methods:** Exenatide (5 µg, sc) or saline (0.2 mL, sc) was administered to 62 healthy volunteers.
30 Frequently sampled intravenous glucose tolerance tests were conducted to assess the impact
31 of exenatide on insulin secretion and insulin action. This pilot study was designed as a
32 crossover study in which participants received exenatide and saline in random order.

33 **Results:** Exenatide increased first phase insulin secretion 1.9-fold ($p=1.9 \times 10^{-9}$) and accelerated
34 the rate of glucose disappearance 2.4-fold ($p=2 \times 10^{-10}$). Minimal model analysis demonstrated
35 that exenatide increased glucose effectiveness (S_g) by 32% ($p=0.0008$) but did not significantly
36 affect insulin sensitivity (S_i). The exenatide-induced increase in insulin secretion made the
37 largest contribution to inter-individual variation in exenatide-induced acceleration of glucose
38 disappearance while inter-individual variation in the drug effect on S_g contributed to a lesser
39 extent ($\beta=0.58$ or 0.27 , respectively).

40 **Conclusions:** This pilot study provides validation for the value of an FSIGT (including minimal
41 model analysis) to provide primary data for our ongoing pharmacogenomic study of
42 pharmacodynamic effects of semaglutide (NCT05071898). Three endpoints provide quantitative
43 assessments of GLP1R agonists' effects on glucose metabolism: first phase insulin secretion,
44 glucose disappearance rates, and glucose effectiveness.

45

46 **Registration:** NCT02462421 (clinicaltrials.gov)

47 **Funding:** American Diabetes Association (1-16-ICTS-112); National Institute of Diabetes and
48 Digestive and Kidney Disease (R01DK130238, T32DK098107, P30DK072488)

49 1 | Introduction

50 Head-to-head comparative effectiveness studies demonstrate that diabetes drugs are not
51 strongly differentiated with respect to their effectiveness to decrease mean HbA1c ¹.
52 Nevertheless, individual patients vary widely in their responses to individual therapies. For
53 example, semaglutide (1.0 mg/wk) decreased HbA1c by an average of 1.64% (SEM \approx 0.05%;
54 SD \approx 0.95%) in patients with baseline HbA1c=8.17% ². The observed magnitude of standard
55 deviation suggests that some patients experienced little if any decrease in HbA1c while others
56 experienced >2.5% HbA1c-lowering. This inter-individual variation may result from genetics,
57 environment, or interplay between both factors. Pharmacogenetics has potential to guide
58 treatment decisions, enabling clinicians to recommend optimal therapy for individual patients
59 based on individualized predictors of responsiveness and susceptibility to adverse effects ¹.
60 Pharmacogenomic studies have identified genetic variants associated with the magnitude of
61 responses to several diabetes drugs, including metformin, sulfonylureas, and GLP1 receptor
62 agonists ³⁻⁷. While some genetic variants alter a drug's pharmacokinetics, other genetic variants
63 alter pharmacodynamics by altering functions of proteins that mediate drug responses. Although
64 genetic variation in pharmacokinetics may be less relevant for responses to an injectable
65 peptide drug such as exenatide, genetic variants in the *GLP1R* gene have been reported to be
66 associated with pharmacodynamic responses to GLP1 receptor agonists ⁴⁻⁷.
67 We initiated this clinical trial as a pilot and feasibility study for our ongoing genome-wide
68 association study of responses to semaglutide (NCT05071898). Specifically, we conducted
69 frequently sampled intravenous glucose tolerance tests (FSIGT) to assess pharmacodynamic
70 responses to a rapid-acting GLP1R agonist (exenatide): glucose-stimulated insulin secretion
71 and the rate of glucose disappearance. We applied the "minimal model" to analyze FSIGT data.
72 This mathematical model describes the time course for plasma glucose levels to return to

73 baseline after an intravenous glucose challenge as a function of the time course of glucose-
74 stimulated insulin secretion and two parameters: insulin sensitivity (S_i) and glucose
75 effectiveness (S_g)⁸. S_g reflects insulin-independent mechanisms whereby plasma glucose
76 concentration drives the return of plasma glucose to baseline levels during an FSIGT. Herein we
77 summarize pharmacodynamic responses to exenatide in the overall study population as well as
78 in sub-groups who were homozygous for two genetic variants, *GIPR* (p.E354Q; rs1800437) and
79 *GCGR* (p.G40S; rs850763). The choice of these two candidate genes was inspired by intriguing
80 observations suggesting interactions among GLP1, GIP, and glucagon⁹. Specifically, peptide
81 drugs that target multiple receptors (GLP1R, GIPR, and GCGR) are reported to exert stronger
82 pharmacological effects than selective drugs targeting only one receptor⁹. Just as exogenous
83 administration of agonists targeting GIPR and GCGR enhance pharmacological responses to an
84 exogenous GLP1R agonist, we hypothesized that response to an exogenous GLP1R agonist
85 might be modulated by effects of endogenous agonists mediated by GIPR and/or GCGR. We
86 focused on two variants (rs1800437 and rs850763), which have been reported to alter the
87 function of GIPR and GCGR, respectively^{10,11}.

88

89 2 | Methods

90 2.1 | Study population: recruitment and screening

91 The Old Order Amish population of Lancaster County, PA emigrated from Central Europe in the
92 early 1700's. University of Maryland School of Medicine researchers have been studying
93 genetic determinants of cardiometabolic health in this population since 1993. To date, ~10,000
94 Amish adults participated in one or more studies as part of the Amish Complex Disease
95 Research Program ([http://www.medschool.umaryland.edu/endocrinology/Amish-Research-
96 Program/](http://www.medschool.umaryland.edu/endocrinology/Amish-Research-Program/)). These studies generated a genotype database that was used to identify individuals
97 with any of three genotypes who were eligible for our clinical trial: (a) homozygotes for a
98 missense variant in *GIPR* (p.E354Q; rs1800437); (b) homozygotes for a missense variant in
99 *GCGR* (p.G40S; rs850763); and (c) individuals who were homozygous for the “wild type” major
100 alleles of *GIPR* and *GCGR*. A research nurse, accompanied by a member of the Amish
101 community, made home visits to invite individuals to participate in the study. If they expressed
102 interest, the study was explained in detail; potential participants were invited to sign an informed
103 consent form. Thereafter, the research nurse obtained a medical history; measured height,
104 weight and blood pressure; and obtained blood samples for screening laboratory tests
105 (hematocrit, fasting plasma glucose, serum creatinine, serum AST, serum ALT, plasma TSH,
106 and HbA1c).

107 2.2 | Study design: overview

108 The study was designed as a crossover study in which healthy individuals were randomized
109 between administration of exenatide (5 µg, sc) or saline (0.2 mL, sc). Fifteen minutes after the
110 injections, participants underwent a frequently sampled intravenous glucose tolerance test
111 (FSIGT) as described in the Supplementary Appendix. A second FSIGT was conducted 5-28
112 days later; each participant received the treatment (either saline or exenatide) not administered

113 for the first FSIGT. All procedures were reviewed and approved by the University of Maryland
114 Baltimore IRB.

115 Practical considerations guided our selection of exenatide as the GLP1R agonist for this pilot
116 study. Exenatide is rapidly absorbed and could be administered 15 min prior to initiation of the
117 FSIGT. In contrast, liraglutide (the principal alternative in 2015 when this study was initiated)
118 achieves C_{max} ~10-12 hours after injection¹². The logistics of administering an injection 10-12
119 hours prior to the FSIGT would have been challenging in this out-patient study.

120 2.3 | Power calculations

121 We aimed to recruit 24 research participants for each of the three genotypes. We estimated that
122 these recruitment targets provided 80% power (with $p=0.05$) to detect association with a 35%
123 change in first-phase insulin secretion and a 25% change in glucose disappearance rate for
124 homozygous variant compared to homozygous wild-type individuals. However, the clinical trial
125 was terminated early when it became apparent that we would not meet our recruitment targets
126 within the available budget.

127 2.4 | Eligibility criteria

128 To be eligible to participate in the clinical trial, individuals were required to be of Amish descent,
129 at least 18 years old, and have BMI between 18-40 kg/m². Exclusion criteria are summarized in
130 the Supplementary Appendix.

131 2.5 | Clinical chemistry

132 Processing of blood samples and laboratory methods are summarized in the Supplementary
133 Appendix.

134 2.6 | Data and statistical analyses

135 We established two primary end points: drug effects on (a) first phase insulin secretion and (b)
136 glucose disappearance rate. Fig. 1 presents untransformed data on plasma levels of insulin and
137 glucose. Tables 1 and 2 present analyses of logarithmic transformation of data on AIR_g , S_i , S_g ,
138 and glucose disappearance rates because the untransformed data were not normally
139 distributed. Data in all the other Figures and Tables were inverse normally transformed and
140 multiplied by SD to have effect size in real units; all analyses in those Figures and Tables were
141 adjusted for age, sex, and BMI. Genetic association analysis (Table S3) was performed using
142 linear mixed models to account for familial correlation using the kinship relationship matrix as
143 implemented in the Mixed Model Analysis for Pedigree and population [<https://mmap.github.io/>].
144 Multiple regression analysis was conducted using Excel. Minimal model analyses were
145 conducted as described elsewhere ¹³⁻¹⁵. Minimal model analysis of the FSIGT data was used to
146 estimate indices of glucose effectiveness (S_g) and insulin sensitivity (S_i) as previously described
147 using MINMOD software (version 6.02) (MinMOD Millenium, Los Angeles, CA) ¹⁵. AIR_g is
148 calculated as the area under the curve for first phase insulin secretion between 0-10 minutes.
149 Disposition Index was calculated as the product of S_i multiplied by AIR_g ⁸.

150 Statistical significance was assessed using a paired t-test. Although a p-value of $p < 0.05$ was
151 defined as the threshold for nominal statistical significance, a more stringent threshold (e.g.,
152 $p < 0.001$) may be appropriate to account for multiple comparisons.

153 3 | Results

154 3.1 | Disposition and adverse events

155 Research participants' baseline characteristics are summarized in Table S1. Disposition of
156 participants and adverse events are summarized in Fig. S1. Seventy-eight individuals were
157 enrolled in this clinical trial between June, 2016 - November, 2018. Sixty-two participants
158 completed frequently sampled intravenous glucose tolerance tests.

159 3.2 | Intravenous glucose tolerance tests: impact of exenatide

160 Intravenous administration of glucose triggered prompt increases in plasma levels of glucose
161 and insulin (Fig. 1). Plasma glucose achieved a peak at ~4 min – after which time glucose levels
162 decreased. Administration of exenatide augmented insulin secretion. We defined indices to
163 quantitate exenatide's direct effect on glucose-stimulated insulin secretion and exenatide's
164 indirect effect on the rate of glucose disappearance (Table S2). As illustrated by the time course
165 of insulin levels in exenatide-treated individuals (Fig. 1), insulin secretion was biphasic.
166 Consistent with published literature^{12,16}, the area-under-the-curve (AUC) between 0-10 min
167 provides an index of first phase insulin secretion (Table S2). We used AUC between 10-50 min
168 as an index of second phase insulin secretion. The higher plasma insulin levels observed in
169 exenatide-treated individuals accelerated the rate at which glucose levels declined. During the
170 time interval between 25-50 min, the plot of log(glucose) versus time approximates a straight
171 line. The slope of that line served as index of the rate of glucose disappearance (Table S2)¹².
172 Exenatide triggered statistically significant increases in the areas under the curve (AUCs) for
173 first phase (~1.9-fold; $p=1.9 \times 10^{-9}$; Fig. S2) and second phase (~3.5-fold; $p=1 \times 10^{-9}$) insulin
174 secretion as well as the rate of glucose disappearance (~2.4-fold; $p=2 \times 10^{-10}$; Fig. S2). Values for
175 first phase and second phase insulin secretion were closely correlated ($r=0.74$, $p=2.4 \times 10^{-10}$ for
176 placebo data; $r=0.63$, $p=3.4 \times 10^{-7}$ for data after administration of exenatide) (Fig. S3).

177 Because curves describing time courses for mean glucose levels in the placebo and exenatide
178 studies are essentially superimposable during the first ten minutes (Fig. 1), the drug effect on
179 first phase insulin secretion likely represents a direct effect of exenatide. In contrast, exenatide's
180 effect on second phase insulin secretion (10-50 min) likely reflects a balance between
181 exenatide's positive direct effect on insulin secretion and the negative impact of lower glucose
182 levels tending to decrease insulin secretion. Accordingly, we emphasized first phase insulin
183 secretion to assess the correlation between insulin secretion and the rate of glucose
184 disappearance. The rate of glucose disappearance (as defined in Table S2) was correlated with
185 first phase insulin secretion ($r=0.74$, $p=2.4 \times 10^{-10}$ for placebo data; $r=0.63$, 3.4×10^{-7} for data
186 after administration of exenatide) (Fig. 2AB). As illustrated in the histograms (Fig. S4), we
187 observed substantial inter-individual variation in indices for drug effects on both stimulation of
188 insulin secretion and acceleration of glucose disappearance. While exenatide exerted little or no
189 effect in some individuals, greater than 5-fold increases were observed in other individuals.

190 3.2 | Intravenous glucose tolerance tests: exenatide increases glucose effectiveness

191 Exenatide's effect on the rate of glucose disappearance was correlated with the magnitude of
192 exenatide's effect on insulin secretion ($r=0.70$; $p=9.2 \times 10^{-9}$) (Fig. 2C). The correlation coefficient
193 suggests that inter-individual variation in the magnitude of exenatide's direct effect on insulin
194 secretion explains approximately half of the observed variance in the magnitude of exenatide's
195 indirect effect on the rate of glucose disappearance. Accordingly, we searched for other factors
196 that might have contributed to variation in the effect of exenatide to accelerate glucose
197 disappearance. We applied Bergman's minimal model^{8,15,17,18} to estimate insulin sensitivity (S_i),
198 glucose effectiveness (S_g), and disposition index (DI) (Table 1). Although acute administration of
199 exenatide did not alter insulin sensitivity ($p=0.36$), exenatide treatment increased glucose
200 effectiveness by 32% ($p=0.0008$), acute insulin response to glucose by 94% ($p=2.3 \times 10^{-10}$) and
201 disposition index by 95% ($p=2.0 \times 10^{-6}$). The rate of glucose disappearance was significantly

202 correlated with glucose effectiveness for data from both placebo studies ($r=0.50$, $p=0.0001$; Fig.
203 3) and exenatide studies ($r=0.66$, $p=5.4 \times 10^{-8}$; Fig. 3). We conducted multiple regression
204 analyses to further investigate inter-relationships among the parameters of the minimal model in
205 the context of acute administration of exenatide. In the placebo state, inter-individual variation in
206 in S_i or AIR_g each made similar magnitude contributions to inter-individual variation the rate of
207 glucose disappearance. An increase of 1 standard deviation unit (SDU) in S_i or AIR_g was
208 associated with an increase of ~ 0.4 SDU in the rate of glucose disappearance (Table 2). Inter-
209 individual variation in glucose effectiveness made a smaller contribution (i.e., 0.2 SDU increase
210 in glucose disappearance rates for each SDU increase in S_g) (Table 2). After exenatide
211 administration, variation in all three parameters also contributed, but the effect of variation in
212 AIR_g predominated (an increase of 0.61 SDU in the rate of glucose disappearance per 1 SDU
213 increase in insulin secretion); the impact of variations in insulin sensitivity and glucose
214 effectiveness were smaller (Table 2). Variation in the magnitude of the drug effect on insulin
215 secretion was the principal determinant of the magnitude of the drug effect on the rate of
216 glucose disappearance. An increase of 1 SDU in the drug effect on AIR_g was associated with an
217 increase of 0.58 ± 0.12 SDU in the magnitude of the drug effect for the rate of glucose
218 disappearance ($p=7.2 \times 10^{-7}$) (Table 2).

219 3.3 | Effect of genotype

220 This pilot study was designed to test the hypothesis that missense variants in two candidate
221 genes (*GCCR* and *GIPR*) might be associated with pharmacodynamic responses to GLP1
222 receptor agonists. Table S3 compares pharmacodynamic responses to exenatide among three
223 groups of people: (a) individuals who are homozygous for the major alleles of both genes; (b)
224 homozygotes for the G40S variant of *GCCR* (rs1801483)^{11,19}; and (c) homozygotes for the
225 E354Q variant of *GIPR* (rs1800437)^{10,20,21} (Table S3). Four co-primary endpoints were pre-
226 specified: association of genotype (either G40S-*GCCR* or E354Q-*GIPR*) with the magnitude of

227 drug effect (i.e., either exenatide-induced augmentation of first phase insulin secretion or
228 exenatide-induced acceleration of the rate of glucose disappearance). We did not observe
229 statistically significant associations between any of the genetic variants and either of the
230 endpoints.

231

232 4 | Discussion

233 Pharmacogenomic research has utilized varied approaches – including acute studies in healthy
234 volunteers assessing acute pharmacodynamic endpoints^{3,22} and chronic studies in disease
235 patients assessing routine clinical endpoints such as HbA1c²³. Short-term studies in healthy
236 volunteers offer several methodological advantages – for example, minimization of confounding
237 factors caused by co-existing diseases or effects of changing co-medications during the course
238 of the study. This pilot study provided an opportunity to validate pharmacodynamic endpoints for
239 our currently ongoing genome-wide association study of the genetics of pharmacodynamic
240 responses to a GLP1 receptor agonist (NCT05071898). As exemplified by the usual stepwise
241 approach to drug development, it is informative to conduct pilot studies to validate methods and
242 analytic approaches before initiating a larger clinical trial. Our results confirm the existence of
243 substantial inter-individual variation in pharmacodynamic responses to exenatide – ranging from
244 no significant increase to a 5- to 6-fold increase for glucose-sensitive insulin secretion or
245 acceleration of glucose disappearance, respectively. The wide range of inter-individual variation
246 in the magnitude of drug response emphasizes the potential value of identifying genetic variants
247 to predict an individual's pharmacological response and provide guidance to physicians in
248 selecting the best diabetes drug for each individual patient.

249 FDA-approved prescribing information for GLP1R agonists identifies several important clinical
250 benefits for this class of drugs: HbA1c-lowering in patients with type 2 diabetes, weight loss in
251 overweight/obese patients, and decreasing major adverse cardiovascular events in patients with
252 type 2 diabetes²⁴⁻²⁶. Our clinical trial assessed drug-induced acceleration of glucose
253 disappearance in healthy non-diabetic individuals, which is mechanistically related to drug-
254 induced HbA1c lowering in patients with type 2 diabetes. Mediation analysis of the LEADER
255 cardiovascular outcome trial suggested that ~90% of liraglutide's beneficial impact on
256 cardiovascular risk reduction was mediated by the drug-induced decrease in HbA1c²⁷. This

257 suggests that genetic variants associated with glycemic effects may also contribute to predicting
258 the magnitude of cardiovascular risk reduction. Comparative effectiveness confirmed that
259 GLP1R agonists providing the largest HbA1c-lowering also provided the greatest
260 cardioprotection^{28,29}.

261 4.1 | Acute exenatide-induced acceleration of glucose disappearance: mechanisms

262 Exenatide increased the magnitude of the mean glucose-stimulated 1st phase insulin secretion
263 by 1.9-fold, 3.5-fold increase for 2nd phase insulin secretion, and 2.1-fold increase for the
264 glucose disappearance rate (Figs. 1 and S2; Table 1). Furthermore, exenatide caused a 32%
265 increase in mean glucose effectiveness (S_g) but did not induce a significant change in mean
266 insulin sensitivity (Table 1). The impact of the exenatide-induced increase in S_g is supported by
267 the observation that rates of glucose disappearance were correlated with the magnitude of S_g in
268 both placebo studies and studies conducted after participants received exenatide (Fig. 3).
269 Multiple regression analysis revealed that inter-individual variation in the magnitudes of glucose-
270 stimulated insulin secretion and insulin sensitivity appeared to contribute significantly to inter-
271 individual variation in the rate of glucose disappearance in both placebo studies and studies
272 conducted after participants received exenatide (Table 2). Thus, although exenatide does not
273 exert an acute effect on insulin sensitivity, pre-existing inter-individual variation in S_i does
274 contribute significantly to inter-individual variation in rates of glucose disappearance both at
275 baseline and in the exenatide-treated states (Table 2). Notwithstanding smaller contributions
276 from S_g and S_i , inter-individual variation in the magnitude of exenatide-induced increase in
277 glucose-sensitive insulin secretion (AIR_g) was quantitatively the most important determinant of
278 the magnitude of the drug-induced increase in glucose disappearance (Table 2); a change of 1
279 SDU in the drug effect on AIR_g was associated with a 0.58 SDU in the drug effect on the rate of
280 glucose disappearance. These data on effects of exenatide on sub-phenotypes (i.e., insulin
281 secretion and glucose disappearance rate) are generally similar to what has been reported for

282 liraglutide and lixisenatide ^{12,16} with the exception that lixisenatide was reported not to induce a
283 statistically significant increase in 2nd phase insulin secretion in healthy individuals ¹⁶. Consistent
284 with previous studies of GLP1R agonists ^{12,16,30,31}, we did not detect a significant effect of
285 exenatide on the mean insulin sensitivity index (S_i). The selectivity of the exenatide-induced
286 increase in S_g without affecting S_i supports the conclusion that S_i and S_g reflect distinct aspects
287 of glucose metabolism ⁸.

288 The term “glucose effectiveness” refers to insulin-independent mechanisms whereby glucose
289 concentrations enhance glucose utilization and/or decrease glucose production ⁸. The precise
290 physiological mechanisms mediating glucose effectiveness are not completely understood ⁸.
291 There has been discussion about challenges in estimating glucose effectiveness from data
292 derived from intravenous glucose tolerance tests. For example, it has been suggested that
293 higher levels of insulin secretion may lead to higher mathematical estimates of glucose
294 effectiveness; it has been challenging to identify detailed mechanisms accounting for these
295 higher estimates of S_g ^{32,33}. Nevertheless, it is theoretically possible that the exenatide-induced
296 increase in insulin secretion may contribute to the larger mathematical estimates of S_g . Bergman
297 ⁸ has suggested that glucose effectiveness may reflect hepatic glucose uptake and metabolism
298 (mediated by GLUT2 and glucokinase). As GLP1 receptor agonists have been reported to
299 suppress glucagon levels ³⁴, this might provide an endocrine mechanism whereby exenatide
300 might exert an indirect effect on hepatic glucose metabolism. However, to the extent that effects
301 of exenatide on glucagon secretion by α -cells might be mediated at least in part by paracrine β -
302 cell insulin secretion, such an effect would not necessarily be entirely independent of insulin. In
303 any case, further research will be required to elucidate physiological mechanisms mediating
304 acute effects of GLP1 receptor agonists on glucose effectiveness.

305 4.2 | Pharmacogenomic candidate genes

306 A missense variant in the *GLP1R* gene (rs6923761; p.T149M) has previously been reported to
307 be associated with a diminished response to GLP1 receptor agonists^{6,7,35}. We have not
308 detected this variant in DNA sequences in the Old Order Amish. Recent literature has
309 suggested the existence of positive crosstalk among GLP1, GIP, and glucagon with respect to
310 their beneficial effects on insulin secretion and weight loss³⁶. These considerations led to the
311 design of tirzepatide – a recently approved “twincretin” combining agonist activity against both
312 GLP1R and GIPR³⁷. Based on these data, we hypothesized that there might be
313 pharmacologically relevant interactions between an exogenous GLP1R agonist and
314 endogenous glucagon or GIP. To test these hypotheses, we recruited individuals who are
315 homozygous for two relatively common missense variants: rs1801483 (p.G40S) in *GCGR* and
316 rs1800437 (p.E354Q) in *GIPR*. The p.E354Q variant in *GIPR* has been reported to enhance
317 agonist-induced receptor desensitization – potentially leading to resistance to the effect of GIP
318 agonists¹⁰. Furthermore, this genetic variant in *GIPR* has been reported to be associated with
319 increased plasma levels of GIP as well as various anthropometric and glycemic traits³⁸. The
320 p.G40S variant in *GCGR* has been reported to impair signaling through β -arrestin-1¹¹. This
321 p.G40S variant in *GCGR* has been reported to be associated with diabetes¹⁹ although this
322 finding has not been reproducible³⁹.

323 Although we observed 15-20% numerical decreases in the magnitudes of the effect of
324 exenatide-induced effect on second phase glucose-stimulated insulin secretion in homozygotes
325 for variants in both *GIPR* (rs1800437) and *GCGR* (rs1801483), these numerical differences
326 were not statistically significant (Table S3). We encountered greater than expected difficulty in
327 recruiting research participants with genotypes of interest. The small size of the study
328 population creates uncertainty about the interpretation of our observations – i.e., whether the
329 statistically insignificant numerical trends toward a decrease in the response to exenatide might
330 represent type II error (incorrect rejection of a false null hypothesis). In order to increase power

331 to detect genetic associations, this study focused on homozygotes. Heterozygosity is quite a bit
332 more common and would, therefore, be of greater practical relevance from a pharmacogenomic
333 perspective. Even if one assumes that these variants in *GIPR* or *GCGR* are indeed associated
334 with responses to GLP1R agonists, we conclude that heterozygosity for these variants is
335 unlikely to exert a large, clinically important effect on responses to GLP1R agonists. Further
336 research will be required to resolve these uncertainties. Whether or not the missense variant in
337 *GIPR* alters the response to a selective GLP1R agonist, it would be of considerable interest to
338 determine whether the variant in *GIPR* is associated with variation in response to peptides
339 possessing GIPR agonist activity (including tirzepatide)³⁷.

340

341 **ACKNOWLEDGEMENTS**

342 We gratefully acknowledge funding provided by the American Diabetes Association (grant
343 number 1-16-ICTS-112) and National Institute of Diabetes and Digestive and Kidney Disease
344 (R01DK130238, T32DK098107, and P30DK072488). We also gratefully acknowledge
345 contributions of the research participants and the skilled staff at the Amish Research Clinic for
346 their critical roles in making this study possible. We are grateful to Mary Pavlovich, Melanie
347 Daue, and Kathy Ryan for their help with database management. Dr. Laura Yerges-Armstrong
348 provided genotype data enabling us to identify individuals to be invited to participate in this
349 genotype-guided recruitment study.

350

351 **AUTHORS' CONTRIBUTIONS**

352 Conception of the clinical trial and PI for the grant from the American Diabetes Association grant

353 (1-16-ICTS-112): SIT

354 Acquisition and analysis of data: ALB, AHY, MEM, EAS, SIT, HBW, ZSY

355 Minimal model analysis of FSIGT data: RM, HF

356 Establishment of Old Order Amish genotype database: BDM, ARS

357 Preparation of first draft of manuscript: SIT

358 Revising and approving final version of manuscript: all authors

359 Overall accountability for all aspects of work: SIT

360

361 **Competing Interests**

362 SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor's share of
363 royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. ARS is an
364 employee of Regeneron Genetics Center. BDM and MEM receive grant support from
365 Regeneron Genetics Center. BDM, MEM, EAS, and HBW have received partial salary support
366 from funds provided by RGC. ALB, ZSY, RM, and HF declare no competing interests.

367 **Table 1. Parameters from minimal model analyses.** This Table summarizes data from 45
 368 frequently sampled intravenous glucose tolerance tests conducted after research participants
 369 received either saline (placebo) or exenatide. Data are presented as means \pm SEM. The first
 370 five rows present analyses of untransformed data whereas the next five rows present analyses
 371 of logarithmically transformed data. Paired t-tests were conducted on the logarithmically
 372 transformed data; two-sided p-values are presented in the last column of the Table. Rates of
 373 glucose disappearance were calculated as described in Table S2. Except for one participant
 374 with S_i of 0.16, the remaining participants' S_i values ranged from $1.4\text{-}17.2 \times 10^{-4} \cdot \text{min}^{-1} / [\mu\text{U}/\text{mL}]$
 375 as compared to a published reference range of $1.4\text{-}25.7 \times 10^{-4} \cdot \text{min}^{-1} / [\mu\text{U}/\text{mL}]$ in lean
 376 individuals ¹⁸.

377
 378

Parameter	Placebo	Exenatide	p-value
Insulin sensitivity (S_i)^a	6.80 \pm 0.60	7.07 \pm 0.58	
Glucose effectiveness (S_g)^b	0.0139 \pm 0.0010	0.0183 \pm 0.010	
Acute insulin response (AIR_g)^c	243 \pm 24	472 \pm 56	
Disposition index (DI)	1454 \pm 157	2833 \pm 288	
Glucose disappearance rate^d	506 \pm 31	1060 \pm 70	
Log (S_i)	0.73 \pm 0.05	0.78 \pm 0.04	0.36
Log (S_g)	-1.92 \pm 0.04	-1.76 \pm 0.03	0.0008
Log (AIR_g)	2.31 \pm 0.04	2.58 \pm 0.04	2.3×10^{-10}
Log (DI)	3.04 \pm 0.05	3.36 \pm 0.04	2.0×10^{-6}
Log (glucose disappearance rate)	2.66 \pm 0.03	2.96 \pm 0.04	1.4×10^{-13}

379
 380 ^a units: $10^{-4} \cdot \text{min}^{-1} / [\mu\text{U}/\text{mL}]$
 381 ^b units: min^{-1}
 382 ^c units: $\mu\text{U} \cdot \text{mL}^{-1} \cdot \text{min}^{-1}$
 383 ^d units: $10^{-5} \cdot \text{min}^{-1}$

384 **Table 2. Relative contributions to the rate of glucose disappearance: beta coefficients**
 385 **from multiple regression of parameters derived from minimal model analysis.** The Table
 386 presents results of multiple regression analyses with three independent variables derived from
 387 minimal model analysis of frequently sampled intravenous glucose tolerance tests. The first two
 388 columns present data on logarithmically transformed values of insulin sensitivity (S_i), glucose
 389 effectiveness (S_g), and acute insulin response to glucose ($AI R_g$) in studies where participants
 390 received either saline (placebo) or exenatide. The last column presents analysis of
 391 logarithmically transformed data on effects of exenatide (i.e., “drug effects” calculated as
 392 specified in Table S2) on insulin sensitivity (S_i), glucose effectiveness (S_g), and acute insulin
 393 response to glucose ($AI R_g$). In each analysis, the dependent variable was the rate of glucose
 394 disappearance as defined in Table S2. Beta values are expressed in standard deviation units
 395 (SDU) – i.e., the change in the dependent variable relative to the change in the independent
 396 variable in SDU. The last row of the Table presents the overall two-sided p-value for each
 397 multiple regression model as calculated using Excel. The footnotes indicate two-sided p-values
 398 for each of the coefficients. Units for the minimal model parameters are summarized in Table 1.

399
400

Parameter	Placebo	Exenatide	Drug Effect
Insulin sensitivity (S_i)	0.39 ± 0.16 ^d	0.37 ± 0.09 ^c	0.14 ± 0.11 ^e
Glucose effectiveness (S_g)	0.20 ± 0.16 ^{gd}	0.21 ± 0.09 ^f	0.27 ± 0.13 ^g
Acute insulin response ($AI R_g$)	0.41 ± 0.15 ^c	0.61 ± 0.13 ^b	0.58 ± 0.12 ^a
p-value	0.009	1.9x10 ⁻⁶	5.3x10 ⁻⁸


401
402
403
404

^a p=7.2 x 10⁻⁷; ^b p=0.0004; ^c p=0.01 ^d p=0.02; ^e p=0.03; ^f p=0.15; ^g p=0.23

405 **Figure 1. Exenatide enhances insulin secretion and accelerates the rate of glucose**
406 **disappearance decrease in frequently sampled intravenous glucose tolerance tests**
407 **(FSIGT).**


408 Fifty-three non-diabetic healthy volunteers participated in a randomized crossover study of
409 exenatide (N=53). After an overnight fast, participants were randomly assigned to receive either
410 exenatide (5 µg, s.c.; solid circles) or saline (0.2 mL, s.c.; open circles). The FSIGT was initiated
411 15 min after the s.c. injection by administration of glucose (0.3 g/kg, i.v.) over two minutes.
412 Blood samples were obtained for measurement of plasma glucose (panel A) and plasma insulin
413 (panel B) over the course of 180 min after glucose administration as described in the Methods
414 section^{8,13,14,17}. After a washout period of 5-28 days, a second FSIGT was conducted in which
415 the participant received the treatment (either saline or exenatide) not administered for the first
416 FSIGT. Data are presented as means ± SEM.

417
418
419




420
421
422
423

424 **Figure 2. Correlations between the rate of glucose disappearance and first phase insulin**
425 **secretion.** Glucose-stimulated insulin secretion accelerates the rate of glucose disappearance,
426 which in turn provides an “off” signal for insulin secretion. This analysis demonstrates that the
427 index for the rate of glucose disappearance between 25-50 min (Table 1) is correlated with the
428 index for first phase insulin secretion (Table 1) in both the placebo-FSIGT (panel A; $r=0.74$;
429 $p=2.4 \times 10^{-10}$) and the exenatide-FSIGT (panel B; $r=0.63$; $p=3.4 \times 10^{-7}$). Indices for effects of
430 exenatide on first phase insulin secretion and the rate of glucose disappearance are defined in
431 Table 1. The index for exenatide-induced acceleration of glucose disappearance is correlated
432 with the index for exenatide-induced insulin secretion (panel C; $r=0.70$; $p=9.2 \times 10^{-9}$). Indices for
433 1st phase insulin secretion are expressed as logarithms of AUC expressed in the following units:
434 $[(\mu\text{U}/\text{mL}) \cdot \text{min}]$. Indices for glucose disappearance rates are expressed in the following units:
435 $10^{-5} \cdot \text{min}^{-1}$.



439 **Figure 3. Correlation of rate of glucose disappearance with glucose effectiveness (S_g).**
440 Rates of glucose disappearance (vertical axis) are plotted as a function of glucose effectiveness
441 (S_g) (horizontal axis). The correlation coefficients and p-values are indicated in the Figures for
442 the placebo studies (left panel) and the exenatide studies (right panel). Values of S_g are
443 expressed in the following units: min^{-1} . Rates of glucose disappearance were calculated as
444 summarized in Table S2 expressed in the following units ($10^{-5} \cdot \text{min}^{-1}$).



445

446

447 **REFERENCES**

- 448 1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2
449 diabetes: a patient-centered approach: position statement of the American Diabetes
450 Association (ADA) and the European Association for the Study of Diabetes (EASD).
451 *Diabetes Care*. 2012;35(6):1364-1379.
- 452 2. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and Safety of Once-Weekly
453 Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-
454 Week, Open-Label, Randomized Clinical Trial. *Diabetes Care*. 2018;41(2):258-266.
- 455 3. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin
456 pharmacogenomics: current status and future directions. *Diabetes*. 2014;63(8):2590-2599.
- 457 4. Pearson ER. Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes. *Diabet Med*.
458 2021;38(12):e14726.
- 459 5. Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs.
460 *Diabetologia*. 2021;64(6):1201-1212.
- 461 6. Chedid V, Vijayvargiya P, Carlson P, et al. Allelic variant in the glucagon-like peptide 1
462 receptor gene associated with greater effect of liraglutide and exenatide on gastric
463 emptying: A pilot pharmacogenetics study. *Neurogastroenterol Motil*. 2018;30(7):e13313.
- 464 7. Mashayekhi M, Wilson JR, Jafarian-Kerman S, et al. Association of a glucagon-like peptide-
465 1 receptor gene variant with glucose response to a mixed meal. *Diabetes Obes Metab*.
466 2021;23(1):281-286.
- 467 8. Bergman RN. Origins and History of the Minimal Model of Glucose Regulation. *Front*
468 *Endocrinol (Lausanne)*. 2020;11:583016.
- 469 9. Muller TD, Bluher M, Tschop MH, DiMarchi RD. Anti-obesity drug discovery: advances and
470 challenges. *Nat Rev Drug Discov*. 2022;21(3):201-223.

- 471 10. Mohammad S, Patel RT, Bruno J, Panhwar MS, Wen J, McGraw TE. A naturally occurring
472 GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs
473 GIP control of adipose insulin sensitivity. *Mol Cell Biol*. 2014;34(19):3618-3629.
- 474 11. van der Velden WJC, Lindquist P, Madsen JS, et al. Molecular and in vivo phenotyping of
475 missense variants of the human glucagon receptor. *J Biol Chem*. 2022;298(2):101413.
- 476 12. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and
477 tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in
478 healthy male subjects. *Diabetes Care*. 2002;25(8):1398-1404.
- 479 13. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity
480 and resistance in vivo: advantages, limitations, and appropriate usage. *Am J Physiol*
481 *Endocrinol Metab*. 2008;294(1):E15-26.
- 482 14. Quon MJ, Cochran C, Taylor SI, Eastman RC. Non-insulin-mediated glucose disappearance
483 in subjects with IDDM. Discordance between experimental results and minimal model
484 analysis. *Diabetes*. 1994;43(7):890-896.
- 485 15. Fosam A, Yuditskaya S, Sarcone C, Grewal S, Fan H, Muniyappa R. Minimal Model-Derived
486 Insulin Sensitivity Index Underestimates Insulin Sensitivity in Black Americans. *Diabetes*
487 *Care*. 2021;44(11):2586-2588.
- 488 16. Becker RH, Stechl J, Msihid J, Kapitza C. Lixisenatide resensitizes the insulin-secretory
489 response to intravenous glucose challenge in people with type 2 diabetes--a study in both
490 people with type 2 diabetes and healthy subjects. *Diabetes Obes Metab*. 2014;16(9):793-
491 800.
- 492 17. Beard JC, Bergman RN, Ward WK, Porte D, Jr. The insulin sensitivity index in nondiabetic
493 man. Correlation between clamp-derived and IVGTT-derived values. *Diabetes*.
494 1986;35(3):362-369.

- 495 18. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin
496 sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.
497 *Diabetes*. 1993;42(11):1663-1672.
- 498 19. Hager J, Hansen L, Vaisse C, et al. A missense mutation in the glucagon receptor gene is
499 associated with non-insulin-dependent diabetes mellitus. *Nat Genet*. 1995;9(3):299-304.
- 500 20. Fortin JP, Schroeder JC, Zhu Y, Beinborn M, Kopin AS. Pharmacological characterization of
501 human incretin receptor missense variants. *J Pharmacol Exp Ther*. 2010;332(1):274-280.
- 502 21. Gabe MBN, van der Velden WJC, Gadgaard S, et al. Enhanced agonist residence time,
503 internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor
504 desensitization and long-term impairment of the GIP system. *Basic Clin Pharmacol Toxicol*.
505 2020;126 Suppl 6:122-132.
- 506 22. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19
507 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA*.
508 2009;302(8):849-857.
- 509 23. Zhou K, Yee SW, Seiser EL, et al. Variation in the glucose transporter gene SLC2A2 is
510 associated with glycemic response to metformin. *Nat Genet*. 2016;48(9):1055-1059.
- 511 24. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in
512 type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*.
513 2019;394(10193):121-130.
- 514 25. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients
515 with Type 2 Diabetes. *N Engl J Med*. 2016;375(19):1834-1844.
- 516 26. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes
517 in Type 2 Diabetes. *N Engl J Med*. 2016;375(4):311-322.
- 518 27. Buse JB, Bain SC, Mann JFE, et al. Cardiovascular Risk Reduction With Liraglutide: An
519 Exploratory Mediation Analysis of the LEADER Trial. *Diabetes Care*. 2020;43(7):1546-1552.

- 520 28. Taylor SI. GLP-1 receptor agonists: differentiation within the class. *Lancet Diabetes*
521 *Endocrinol.* 2018;6(2):83-85.
- 522 29. Aroda VR, Eckel RH. Reconsidering the role of glycaemic control in cardiovascular disease
523 risk in type 2 diabetes: A 21st century assessment. *Diabetes Obes Metab.*
524 2022;24(12):2297-2308.
- 525 30. D'Alessio DA, Kahn SE, Leusner CR, Ensinnck JW. Glucagon-like peptide 1 enhances
526 glucose tolerance both by stimulation of insulin release and by increasing insulin-
527 independent glucose disposal. *J Clin Invest.* 1994;93(5):2263-2266.
- 528 31. Meneilly GS, McIntosh CH, Pederson RA, et al. Effect of glucagon-like peptide 1 on non-
529 insulin-mediated glucose uptake in the elderly patient with diabetes. *Diabetes Care.*
530 2001;24(11):1951-1956.
- 531 32. Cobelli C, Bettini F, Caumo A, Quon MJ. Overestimation of minimal model glucose
532 effectiveness in presence of insulin response is due to undermodeling. *Am J Physiol.*
533 1998;275(6):E1031-1036.
- 534 33. Finegood DT, Tzur D. Reduced glucose effectiveness associated with reduced insulin
535 release: an artifact of the minimal-model method. *Am J Physiol.* 1996;271(3 Pt 1):E485-495.
- 536 34. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the
537 Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. *Endocr Rev.*
538 2021;42(2):101-132.
- 539 35. Maselli D, Atieh J, Clark MM, et al. Effects of liraglutide on gastrointestinal functions and
540 weight in obesity: A randomized clinical and pharmacogenomic trial. *Obesity (Silver Spring).*
541 2022;30(8):1608-1620.
- 542 36. Capozzi ME, DiMarchi RD, Tschop MH, Finan B, Campbell JE. Targeting the
543 Incretin/Glucagon System With Triagonists to Treat Diabetes. *Endocr Rev.* 2018;39(5):719-
544 738.

- 545 37. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in
546 Patients with Type 2 Diabetes. *N Engl J Med*. 2021;385(6):503-515.
- 547 38. Bowker N, Hansford R, Burgess S, et al. Genetically Predicted Glucose-Dependent
548 Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by
549 Distinct Causal Variants in the GIPR Region. *Diabetes*. 2021;70(11):2706-2719.
- 550 39. Huang X, Orho M, Lehto M, Groop L. Lack of association between the Gly40Ser
551 polymorphism in the glucagon receptor gene and NIDDM in Finland. *Diabetologia*.
552 1995;38(10):1246-1248.
- 553

1 **Supplementary Appendix**

2
3 **Acute pharmacodynamic responses to exenatide:**

4 **Drug-induced increases in insulin secretion and glucose effectiveness**

5
6 Simeon I. Taylor MD, PhD¹ | May E. Montasser PhD¹ | Ashley H. Yuen MD¹ |

7 Hubert Fan² | Zhinoosossadat Shahidzadeh Yazdi MD¹ | Hilary B. Whitlatch MD¹ |

8 Braxton D. Mitchell PhD, MPH¹ | Alan R. Shuldiner MD¹ | Ranganath Muniyappa MD PhD² |

9 Elizabeth A. Streeten MD¹ | Amber L. Beitelshees PharmD, MPH¹

10
11 ¹ Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of
12 Maryland School of Medicine, Baltimore, MD 21201, USA

13 ² Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and
14 Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

15
16 Correspondence

17 Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine,
18 Baltimore, MD 21201, USA

19 Email: staylor2@som.umaryland.edu

20
21 Funding information

22 American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and
23 Digestive and Kidney Disease (R01DK130238, T32DK098107, and P30DK072488)

24	<u>Table of Contents</u>	
25	1 Exclusion criteria	p. 3
26	2 Frequently sampled intravenous glucose tolerance tests	p. 4
27	3 Clinical chemistry	p. 5
28	Table S1. Demographics and baseline characteristics of study population	p. 6
29	Table S2. Definition of parameters for statistical analyses	p. 7
30	Table S3. Interactions of genotype with pharmacodynamic responses to exenatide	p. 8
31	Figure S1. CONSORT diagram summarizing disposition of research participants	p. 9
32	Figure S2. Exenatide increases first phase insulin secretion and the rate of glucose	
33	disappearance in frequently sampled intravenous glucose tolerance tests	p. 11
34	Figure S3. Correlations between first and second phase insulin secretion	p. 12
35	Figure S4. Inter-individual variation in magnitude of responses to exenatide: first phase	
36	Insulin secretion and rate of glucose disappearance	p. 13
37		
38	4 References	p. 14

39 1 | Exclusion Criteria

- 40 • Known allergy to exenatide
- 41 • History of diabetes, random glucose >200 mg/dL, or HbA1c \geq 6.5%
- 42 • Significant cardiac, hepatic, pulmonary, or renal disease or other diseases that the
43 investigator judged would make interpretation of the results difficult or increase the risk of
44 participation
- 45 • Seizure disorder
- 46 • Pregnant by self-report or known pregnancy within 3 months of the start of study
- 47 • Currently breast feeding or breast feeding within 3 months of the start of the study
- 48 • Estimated glomerular filtration rate <60 mL/min/1.73m²
- 49 • Hematocrit <35%
- 50 • Liver function tests greater than 2 times the upper limit of normal
- 51 • Abnormal TSH
- 52 • History of pancreatitis or pancreatic cancer. Personal or family history of medullary
53 carcinoma of the thyroid.

54 2 | Frequently sampled intravenous glucose tolerance tests

55 After an overnight fast, participants were transported to the Amish Research Clinic where
56 FSIGTs were performed (1Fo, 2). Two 20-gauge catheters were placed in antecubital veins
57 through which normal saline (60 mL/hr) was administered – one for intravenous administration
58 of D50W and one for obtaining blood samples. The infusion was stopped at times when blood
59 samples were withdrawn. To minimize dilution of blood, small amounts of blood were discarded
60 prior to obtaining blood samples. After placement of intravenous catheters, participants received
61 subcutaneous injections of either exenatide (5 µg, sc) or saline (0.2 mL, sc). Fifteen minutes
62 after the subcutaneous injections, an intravenous bolus of glucose (0.3 g/kg) was infused over
63 two minutes. Thirty-one timed blood samples were obtained between -10- and +180-minutes
64 relative to the i.v. glucose infusion (1). Plasma samples were used to assay levels of glucose
65 and insulin.

66

67 3 | Clinical Chemistry

68 Screening blood samples were obtained by a research nurse during home visits and collected in
69 test tubes as appropriate for each assay: EDTA anticoagulant (purple top tube) for
70 measurement of hematocrit and HbA1c; heparin anticoagulant (green top tube) for
71 measurement of TSH; gray top tubes containing sodium fluoride and potassium oxalate for
72 measurement of fasting plasma glucose; red top tube for collecting serum samples. After
73 placing gray, purple, and green top tubes on ice, blood samples were transported to the clinical
74 laboratory at the Amish Research Clinic (maximum transport time, 2 hours). After centrifugation
75 (3300 rpm for 10 min), plasma/serum was sent on the same day to Quest Diagnostics for assay.
76 Blood samples for the frequently sampled intravenous glucose tolerance test were collected in
77 EDTA-containing purple top tubes for measurement of plasma insulin and in EDTA/oxalate-
78 containing gray top tubes for measurement of plasma glucose. Glucose was measured in
79 duplicate using an YSI glucose analyzer. Insulin was assayed in duplicate following the
80 manufacturer's directions using reagents in kits (#10-1113-01) purchased from Mercodia Inc.

81

82

83 **Table S1. Demographics and baseline characteristics of study population**

Mean ± SEM (range)	Males	Females	Total
N (sample size)	33	21	54
Age (years)	46.0 ± 2.0	52.0 ± 2.1	48.3 ± 1.5
BMI (kg/m²)	27.3 ± 0.6	28.9 ± 0.8	27.9 ± 0.5
HbA1c (%)	5.51 ± 0.6	5.60 ± 0.7	5.54 ± 0.4
Serum creatinine (mg/dL)	0.88 ± 0.02	0.73 ± 0.02	0.82 ± 0.02
eGFR (mL/min/1.73 m²)	101.2 ± 2.2	94.5 ± 3.4	98.6 ± 1.9
Hematocrit (%)	43.6 ± 0.4	39.0 ± 0.5	41.8 ± 0.4
Aspartate amino transferase (U/L)	18.5 ± 0.8	17.4 ± 0.9	18.1 ± 0.6
Alanine amino transferase (U/L)	21.0 ± 1.4	17.3 ± 1.1	19.6 ± 1.0

84

85 **Table S2. Definition of parameters for statistical analyses**

Parameter	Definition
1 st phase insulin secretion	Area under the curve (AUC) for plasma insulin levels (0-10 min) calculated by trapezoidal rule
2 nd phase insulin secretion	Area under the curve for plasma insulin levels (10-50 min) calculated by trapezoidal rule
Glucose disappearance rate	Slope of the plot of the logarithm of glucose concentration versus time (25-50 min) calculated as the slope of the least square fit using Excel.
Drug effect: 1 st phase insulin secretion	Logarithm of AUC for 1 st phase insulin secretion when participant received exenatide – logarithm of AUC for 1 st phase insulin secretion when participant received saline.
Drug effect: 2 nd phase insulin secretion	Logarithm of AUC for 2 nd phase insulin secretion when participant received exenatide <i>minus</i> logarithm of AUC for 2 nd phase insulin secretion when participant received saline.
Drug effect: glucose disappearance rate	Glucose disappearance rate when participant received exenatide <i>minus</i> the glucose disappearance rate when participant received saline.
Log-transformed glucose disappearance rate	Logarithm of slope of the plot of the logarithm of glucose concentration versus time (25-50 min) calculated as the slope of the least square fit using Excel.
Drug effect: log-transformed glucose disappearance rate	Logarithm of glucose disappearance rate when participant received exenatide <i>minus</i> logarithm of the glucose disappearance rate when participant received saline.

86

87 **Table S3. Interactions of genotype with pharmacodynamic responses to exenatide.** Data
 88 are expressed as means \pm SEM. Insulin secretion was calculated as areas under the curve
 89 (AUC) using the trapezoidal rule for times between 0-10 min (1st phase) and 10-50 min (2nd
 90 phase). Three participants were excluded because their genotypes did not correspond to any of
 91 the three groups. Two participants were homozygous for rs1801483 and heterozygous for
 92 rs1800437; one participant was homozygous for rs1800437 and heterozygous for rs1801483.
 93 One participant who was homozygous for rs1801483 was excluded because of missing data. P-
 94 values were calculated using Student's t-test for paired values. To account for the 18 statistical
 95 comparisons in the Table, $p < 0.0025$ was chosen as the criterion for statistical significance.


Treatment	Trait	WT	GCCR Homozygotes (rs1801483)	GIPR Homozygotes (rs1800437)
Placebo	Insulin AUC – 1 st phase ^a	270 \pm 40	244 \pm 27 p=0.52	322 \pm 55 p=0.46
Placebo	Insulin AUC – 2 nd phase ^a	626 \pm 90	629 \pm 74 p=0.98	626 \pm 89 p=0.996
Placebo	Glucose disappearance ^b	489 \pm 36	490 \pm 54 p=0.99	626 \pm 69 p=0.06
Exenatide	Insulin AUC – 1 st phase ^a	567 \pm 90	423 \pm 44 p=0.16	618 \pm 155 p=0.77
Exenatide	Insulin AUC – 2 nd phase ^a	2718 \pm 555	2132 \pm 201 p=0.33	2244 \pm 443 p=0.54
Exenatide	Glucose disappearance ^b	1011 \pm 95	1052 \pm 110 p=0.78	1302 \pm 125 p=0.07
Drug Effect	Insulin AUC – 1 st phase ^a	2.25 \pm 0.31	2.00 \pm 0.24 p=0.52	1.91 \pm 0.27 p=0.44
Drug Effect	Insulin AUC – 2 nd phase ^a	4.49 \pm 0.70	3.84 \pm 0.36 p=0.41	3.71 \pm 0.59 p=0.42
Drug Effect	Glucose disappearance ^b	2.19 \pm 0.24	2.31 \pm 0.27 p=0.73	3.34 \pm 0.17 p=0.27
N	Sample size	19	19	13

96

97 ^a Units of AUC for insulin secretion are $\mu\text{U/ml} \cdot \text{min}$.

98 ^a Units of glucose disappearance are min^{-1} .

99 **Figure S1. CONSORT diagram summarizing disposition of research participants.** Seventy-
100 eight individuals were enrolled in this clinical trial between June, 2016 – November, 2018. Sixty-
101 two participants completed frequently sampled glucose tolerance tests. Twelve enrollees were
102 excluded for the following reasons (Fig. S1): low hematocrit (N=1), abnormal TSH levels (N=5),
103 abnormal liver function tests (N=1), family history of medullary carcinoma of the thyroid (N=1),
104 primary hyperparathyroidism (N=1), low eGFR (N=1), poor venous access (N=1), and treatment
105 with warfarin (N=1). Thus, 66 individuals were judged to be eligible for the clinical trial. Three
106 individuals changed their minds and withdrew from the study after providing informed consent
107 but before undergoing an intravenous glucose tolerance test; technical challenges during one
108 FSIGT led to withdrawal of an additional participant. The remaining 63 participants completed
109 the study. Ten individuals were excluded from the data base either because of missing data
110 (N=9) or outlier data (N=1). Thus, data from 53 individuals comprised the final database for
111 most of the analyses. Data from eight individuals' placebo FSIGTs could not be analyzed with
112 the Minimal Model software because of issues related to data quality. Accordingly, Minimal
113 Model analysis of the FSIGT was based on data from 45 individuals. There were 27 reported
114 adverse events of mild to moderate severity. Two participants reported feeling light-headed or
115 dizzy in the evening after leaving the Amish Research Clinic; these were classified as probably
116 being related to the study. There were 11 events in which a participant's plasma glucose
117 (determined using a glucometer) was <70 mg/dL (52-63 mg/dL) at the end of an FSIGT. Three
118 participants reported symptoms (weakness, lightheadedness, or not feeling well) 60-90 minutes
119 after receiving intravenous glucose, at which time glucometer readings of 42 – 60 mg/dL were
120 obtained. Symptoms resolved quickly in all cases without intervention, and the FSIGT was not
121 terminated. These were judged to be mild in severity and probably caused by the study.
122




123

124

125 **Figure S2. Exenatide increases first phase insulin secretion and the rate of glucose**
126 **disappearance in frequently sampled intravenous glucose tolerance tests.** Data are
127 presented as means of data for 53 research participants. The boxes encompass the 2nd and 3rd
128 quartiles; the “whiskers” correspond to the top and bottom quartiles (excluding outliers).
129 “Outliers” are depicted by the closed circles. Statistical significance (calculated using a paired t-
130 test) is indicated on the graphs. Areas under the curve for 1st and 2nd phase insulin secretion are
131 expressed in the following units: ($\mu\text{U}/\text{mL}$) \cdot min.


132



133

134

135 **Figure S3. Correlations between first and second phase insulin secretion.** Intravenous
136 glucose triggers a biphasic response in the FSIGT: first phase insulin secretion (0-10 min) and
137 second phase insulin secretion (10-50 min). Data are plotted as the logarithms of the areas
138 under the curves for first and second phase insulin secretion; placebo studies are plotted in the
139 left panel and exenatide studies in the right panel. Values for correlation coefficients (r) and p -
140 values are indicated in the figure. Areas under the curve for 1st and 2nd phase insulin secretion
141 are expressed in the following units: ($\mu\text{U}/\text{mL}$) \cdot min.




142
143
144

145 **Figure S4. Inter-individual variation in magnitude of responses to exenatide: first phase**
146 **insulin secretion and rate of glucose disappearance.** Indices for effects of exenatide on first
147 phase insulin secretion^a and the rate of glucose disappearance^b are defined in Table 1.
148 Histograms depicting inter-individual variation are presented in the left panel for first phase
149 insulin secretion and the right panel for the rate of glucose disappearance.

150 ^a Units of AUC for insulin secretion are $\mu\text{U}/\text{ml} \cdot \text{min}$.

151 ^a Units of glucose disappearance are min^{-1} .



152
153
154

155 **REFERENCES**

156

- 157 1. Muniyappa, R., Lee, S., Chen, H., and Quon, M. J. (2008) Current approaches for assessing
158 insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage Am
159 J Physiol Endocrinol Metab **294**, E15-26 10.1152/ajpendo.00645.2007
- 160 2. Fosam, A., Yuditskaya, S., Sarcone, C., Grewal, S., Fan, H., and Muniyappa, R. (2021)
161 Minimal Model-Derived Insulin Sensitivity Index Underestimates Insulin Sensitivity in Black
162 Americans Diabetes Care **44**, 2586-2588 10.2337/dc21-0490

163